A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer

Xiao X. Wei, Andrew C. Hsieh, Won Kim, Terence Friedlander, Amy M. Lin, Mirela Louttit, Charles J. Ryan

Research output: Contribution to journalArticlepeer-review

24 Scopus citations

Fingerprint

Dive into the research topics of 'A phase I study of abiraterone acetate combined with BEZ235, a dual PI3K/mTOR inhibitor, in metastatic castration resistant prostate cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences